How big is Stoke Therapeutics, Inc.?

As of Jun 18, Stoke Therapeutics, Inc. has a market capitalization of 636.60 million and reported net sales of 190.90 million with a net profit of 50.27 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 229.02 million and total assets of 271.56 million.

As of Jun 18, Stoke Therapeutics, Inc. has a market capitalization of 636.60 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 190.90 million for the latest four quarters, along with a net profit of 50.27 million during the same period.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 229.02 million and total assets amounting to 271.56 million.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for genetic diseases, with a market cap of $636.60 million and recent net sales of $159 million. Key financial metrics include a P/E ratio of 12.00 and a return on equity of 14.36%.

Overview:<BR>Stoke Therapeutics, Inc. is a biotechnology company that develops treatments for genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 159 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 113 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 636.60 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: 14.36% <BR>Price to Book: 1.82<BR><BR>Contact Details:<BR>Address: 3 Preston Ct, BEDFORD MA: 01730-2379 <BR>Tel: 1 781 4308200 <BR>Fax: 1 302 5313150 <BR>Website: https://www.stoketherapeutics.com/

Should I buy, sell or hold Stoke Therapeutics, Inc.?

Who are in the management team of Stoke Therapeutics, Inc.?

As of March 2022, the management team of Stoke Therapeutics, Inc. includes Dr. Seth Harrison (Independent Chairman), Dr. Edward Kaye (CEO), and several Independent Directors: Ms. Jennifer Burstein, Prof. Adrian Krainer, Dr. Arthur Levin, Dr. Garry Menzel, and Ms. Julie Smith. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Stoke Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Seth Harrison, who serves as the Independent Chairman of the Board.<BR>- Dr. Edward Kaye, who is the Chief Executive Officer and a Director.<BR>- Ms. Jennifer Burstein, who is an Independent Director.<BR>- Prof. Adrian Krainer, who is also an Independent Director.<BR>- Dr. Arthur Levin, serving as an Independent Director.<BR>- Dr. Garry Menzel, who is an Independent Director.<BR>- Ms. Julie Smith, another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Stoke Therapeutics, Inc. technically bullish or bearish?

As of September 5, 2025, Stoke Therapeutics, Inc. has a bullish trend supported by positive MACD signals and strong performance, having returned 26.96% over the past month and 113.06% year-to-date, despite some bearish momentum indicated by the weekly RSI and KST.

As of 5 September 2025, the technical trend for Stoke Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD across both weekly and monthly time frames, as well as bullish readings in the Bollinger Bands and On-Balance Volume. However, the weekly RSI indicates bearish momentum, and the KST shows a mildly bearish signal on the monthly chart. The daily moving averages are also bullish, reinforcing the positive outlook.<BR><BR>In terms of performance, Stoke Therapeutics has outperformed the S&P 500 over the past month with a return of 26.96% compared to the S&P's 2.33%, and it has significantly outperformed year-to-date with a return of 113.06% against the S&P's 12.22%.

Is Stoke Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Stoke Therapeutics, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 12 compared to peers, despite a strong year-to-date return of 203.99%.

As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios include a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, which suggest that while the company has some attractive growth potential, it is currently priced higher than its fundamentals warrant.<BR><BR>In comparison to peers, Stoke Therapeutics has a significantly higher P/E ratio of 22.96 compared to CorMedix, Inc. at 18.60, which is considered very attractive, and Taysha Gene Therapies, Inc. which is deemed risky with a negative P/E. This disparity highlights that Stoke is trading at a premium relative to its more favorably valued peers. Additionally, Stoke Therapeutics has outperformed the S&P 500 over multiple periods, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, but this strong performance does not mitigate its current overvaluation.